Results 231 to 240 of about 696,518 (307)

Complete response to pembrolizumab in a paediatric patient with Lynch syndrome-associated colorectal cancer: a case report and review of immunotherapy-related bowel obstruction. [PDF]

Drugs Context
Ruggiero A, Fuccillo F, Maurizi P, Romano A, Talloa D, Mastrangelo S, Basso M, Briganti V, Giustiniani MC, Persiani R, Attinà G.   +10 more
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Cross-dataset adaptation of voxel-level deep radiomics for predicting survival in inoperable locally advanced NSCLC treated with immunotherapy. [PDF]

Front Immunol
Wang J, Jiang Z, Ji W, Cheng H, Zhang Z, Dekker A, Wee L, Yan M, Lai X.   +8 more
europepmc   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

Serum ferritin change rate combined with a multidimensional inflammation model for predicting efficacy and survival in extensive-stage small-cell lung cancer patients undergoing immunotherapy: a single-center, retrospective cohort study. [PDF]

Front Immunol
Liu Y, Liu X, Li Y, Li M, Su Y, Chen P.
europepmc   +1 more source

Correction: NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model

Scientific Reports
Yee Peng Phoon, Alexandra A. Wolfarth, Pauline Funchain, Jennifer S. Ko, Donghoon Choi, Eliska Dedkova, Daniela Duarte Bateman, Jessica Corvin, Jan J. Melenhorst, Brian R. Gastman   +9 more
doaj   +1 more source

Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor‐Associated Neutrophils to Sensitize Immunotherapy

Advanced Science, EarlyView.
The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang, Xinyu Qu, Tingting Ren, Tong Wu, Weiyong Gu, Jingxin Ding, Keqin Hua, Junjun Qiu   +7 more
wiley   +1 more source

Real-world outcomes of consolidative radiotherapy following first-line chemo-immunotherapy in metastatic non-small cell lung cancer: a retrospective cohort study. [PDF]

Am J Cancer Res
Qiao Z, Pang L, Zheng H.
europepmc   +1 more source

Targeting Peptostreptococcus anaerobius with an Iron‐Based Nanozyme Reverses Ferroptosis Resistance and Enhances Antitumor Immunity in Colorectal Cancer

Advanced Science, EarlyView.
An iron‐based nanozyme selectively eliminates intratumoral P. anaerobius while catalytically generating ROS to induce ferroptosis, synergistically suppressing colorectal cancer growth and activating anti‐tumor immunity through immunogenic cell death. ABSTRACT The intratumoral microbiota is a critical determinant of therapeutic outcomes in colorectal ...
Yinghao Cao, Jun Wang, Hanwenchen Wang, Xiang Sun, Fang Fang, Shiying Li, Jianping Liu, Changrong Shi, Pengyuan Qi, Jianhua Zou, Xiaoyuan Chen, Kailin Cai   +11 more
wiley   +1 more source

Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study. [PDF]

J Clin Med
Mildanoglu MM, Yucel MH, Engin Delipoyraz E, Sunger E, Ozcelik H, Fidan S, Terzioglu C, Muglu H, Hamdard J, Cakan Demirel B, Kutlu Y, Acikgoz O, Seker M, Bilici A.   +13 more
europepmc   +1 more source